15 Biggest Mid-Day Gainers For Thursday - Affimed (NASDAQ:AFMD)

GlycoMimetics Inc GLYC shares jumped 67.6 percent to $9.00 as the company reported that GMI-1271 has received the FDA Breakthrough therapy designation for adult relapsed/refractory acute myeloid leukemia.
athenahealth, Inc ATHN shares surged 16 percent to $123.30 following a 13D filing from Elliott Associates showing a 9.2 percent stake in the company.
Achillion Pharmaceuticals, Inc. ACHN shares gained 14 percent to $4.31. Leerink Swann upgraded Achillion Pharmaceuticals from Market Perform to Outperform.
CytRx Corporation CYTR rose 12.1 percent to $ 0.508. CytRx will present global Phase 3 aldoxorubicin clinical data in patients with soft tissue sarcomas at the 2017 ASCO Annual Meeting.
ImmunoGen, Inc. IMGN shares climbed 11.4 percent to $5.27 as the company disclosed promising new clinical data with mirvetuximab soravtansine in ovarian cancer.
Veritiv Corp VRTV gained 9.2 percent to $43.62. Wells Fargo upgraded Veritiv from Market Perform to Outperform.
Perry Ellis International, Inc. PERY rose 8.5 percent to $19.66 after the company reported stronger-than-expected Q1 results.
Incyte Corporation INCY gained 7.9 percent to $130.02 Incyte disclosed that its IDO1 enzyme inhibitor in combo with Merck's anti-PD-1 therapy is 'well-tolerated and demonstrated durable clinical responses across multiple solid tumors'. The company also announced that first data from combo of epacadostat with Bristol-Myers' opdivo showed that combo is 'well-tolerated and demonstrates promising clinical outcomes in multiple advanced solid tumors.'
Pandora Media Inc P rose 5.3 percent to $9.41. Sirius XM Holdings Inc. SIRI is in talks about bidding for Pandora, according to sources as reported by the New York Post.
L Brands Inc LB gained 5 percent to $50.80 after the company reported upbeat earnings for its first quarter and raised its FY17 outlook.
Syndax Pharmaceuticals Inc SNDX shares gained 5 percent to $14.26 after surging 44.62 percent on Wednesday. Syndax issued results from Phase 2 ENCORE 601 trial of entinostat in combo with Merck's KEYTRUDA for the treatment of advanced melanoma.
Teladoc Inc TDOC shares surged 4.9 percent to $28.90. KeyBanc initiated coverage of Teladoc with an Overweight rating.
Shire PLC (ADR) SHPG shares rose 4 percent to $189.50 after the company disclosed that its lanadelumab study met primary endpoint.
Affimed NV AFMD shares rose 3.4 percent to $2.33. Affimed reported that it will present immune cell engager data at the American Society of Clinical Oncology Annual Meeting and EACR-AACR-SIC Special Conference.
Childrens Place Inc PLCE rose 2.6 percent to $114.50 after the company posted upbeat quarterly profit.

Market News and Data brought to you by Benzinga APIs